Newbury Pharmaceuticals

Prenumeration

Kalender

2024-01-10	Årsstämma 2024
2023-10-11	Bokslutskommuniké 2023
2023-07-07	Kvartalsrapport 2023-Q3
2023-04-12	Kvartalsrapport 2023-Q2
2023-01-12	Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11	Kvartalsrapport 2023-Q1
2023-01-11	Årsstämma 2023
2022-10-13	Bokslutskommuniké 2022
2022-07-06	Kvartalsrapport 2022-Q3
2022-04-13	Kvartalsrapport 2022-Q2

Beskrivning

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Läkemedel & Handel

Newbury Pharmaceuticals är verksamma inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget är verksamma inom den skandinaviska marknaden. Newbury Pharmaceuticals har sitt huvudkontor i Lund.

Filter

År

Typ

Språk

Rensa

2023-01-11 11:45:00 ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB -12,00% | 1,07 MSEK

2023-01-11 08:00:00 Newbury Pharmaceuticals interim report September 2022 – November 2022 -12,00% | 1,07 MSEK

2023-01-09 08:00:00 International sales orders for 2023 -6,05% | 0,33 MSEK

2022-12-27 10:00:00 Fampridine Newbury approved by the Swedish Health Authorities +0,75% | 0,12 MSEK

2022-12-14 08:00:00 Newbury Pharmaceuticals publishes its annual report for 2021/2022 -1,27% | 0,05 MSEK

2022-12-08 12:00:00 Kallelse till årsstämma i Newbury Pharmaceuticals AB -1,27% | 0,07 MSEK

2022-12-06 07:00:00 Redeye will host two events with Newbury Pharmaceuticals in December +4,43% | 0,24 MSEK

2022-11-23 09:30:00 Newbury expands its portfolio with two ready to launch products -1,82% | 0,20 MSEK

2022-11-22 08:00:00 Newbury will participate at the RedEye Life Science Day – 24th November 2022 -0,93% | 0,05 MSEK

2022-11-01 08:30:00 Teriflunomide Newbury approved by the Norwegian Health Authorities +5,15% | 0,14 MSEK

2022-10-13 08:00:00 Newbury Pharmaceuticals year-end report September 2021 – August 2022 +4,31% | 0,23 MSEK

2022-09-07 13:15:00 Newbury Pharmaceuticals management has purchased shares in the company +2,26% | 0,56 MSEK

2022-09-05 15:00:00 Newbury Pharmaceuticals engages Pareto Securities to reduce spread in share price -6,39% | 0,03 MSEK

2022-08-02 14:30:00 Newbury Pharmaceuticals expands the team with a Head of Business Development -0,12% | 0,20 MSEK

2022-07-06 08:00:00 Newbury Pharmaceuticals interim report September 2021 – May 2022 +1,56% | 0,08 MSEK

2022-06-09 07:15:00 Newbury Pharmaceuticals is strengthening its portfolio with Teriparatide injection in pre-filled pen -0,48% | 0,13 MSEK

2022-04-26 08:00:00 Newbury Pharmaceuticals is strengthening its portfolio with two new products -4,56% | 0,03 MSEK

2022-04-13 08:00:00 Newbury Pharmaceuticals interim report September 2021 – February 2022 +0,61% | 0,11 MSEK

2022-03-29 16:30:00 Sunitinib Newbury approved by the Danish Health Authorities +5,11% | 0,35 MSEK

2022-03-07 08:45:00 Lenalidomide Newbury approved by the Swedish Health Authorities -5,00% | 0,09 MSEK

2022-02-21 07:15:00 Commercialisation of Icatibant Newbury -4,71% | 0,12 MSEK

2022-02-15 11:00:00 Newbury on business focus and strategy (Video) -3,33% | 0,15 MSEK

2022-02-07 10:00:00 Export order received -12,54% | 0,43 MSEK

2022-02-04 11:45:00 Ticagrelor Newbury approved by the Norwegian Health Authorities -3,08% | 1,74 MSEK

2022-02-03 11:00:00 Newbury Pharmaceuticals changes ticker (trading code) to NEWBRY

2022-02-02 11:00:00 Newbury Pharmaceuticals has been approved for listing on Nasdaq First North Growth Market

2022-01-31 16:45:00 Newbury Pharmaceuticals publishes a supplementary document prior to scheduled listing on Nasdaq First North Growth Market

2022-01-27 11:30:00 Newbury Pharmaceuticals offering oversubscribed - first day of trading is scheduled for February 4, 2022 on the Nasdaq First North Growth Market

2022-01-11 10:00:00 Newbury Pharmaceuticals AB publishes prospectus regarding offering of newly issued shares prior to listing application on Nasdaq First North Growth Market

2021-12-21 17:15:00 Newbury Pharmaceuticals interim report September 2021 – November 2021

2021-12-14 12:45:00 Newbury Pharmaceuticals signs strategic agreement for treatment of short bowel syndrome in the Nordics and strengthens the strategic focus on rare diseases

2021-12-10 14:00:00 Newbury Pharmaceuticals is strengthening its oncology portfolio

2021-10-21 11:30:00 Newbury Pharmaceuticals is strengthening its portfolio and strategic focus

2021-08-19 08:00:00 Newbury Pharmaceuticals appoints Lars Minor as the new CEO

2021-03-18 08:00:00 Newbury Closes Series A Funding Round

2021-01-27 08:00:00 Newbury Pharmaceuticals enters the Nordics with exciting product portfolio

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Newbury Pharmaceuticals

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden